Full-Time

Vice President

Intellectual Property

Confirmed live in the last 24 hours

4D Molecular Therapeutics

4D Molecular Therapeutics

201-500 employees

Develops gene therapies for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$322k - $394kAnnually

Expert

Oakland, CA, USA

This role is expected to be available for in-office work on a hybrid basis.

Category
Intellectual Property (IP)
Legal & Compliance

You match the following 4D Molecular Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • JD degree or equivalent from an accredited law school
  • PhD in molecular biology, genetics, biochemistry, or other biological field related to the biopharma industry
  • Admission to at least one state bar (preferably CA)
  • Registered to practice before the United States Patent and Trademark Office
  • Strong knowledge of patent, trade secret, and trademark practices, as well as current US and foreign patent, trade secret, and trademark laws
  • 12+ years of patent prosecution experience as an attorney in the life sciences field, particularly in biopharma (can be a combination of law firm and in-house experience)
  • In-house experience in and knowledge of drug development, with expertise in genetic medicines preferred; in-house experience at one or more publicly-traded, commercial-stage biotechnology, pharmaceutical, or biopharmaceutical companies strongly preferred
  • Experience in counseling life sciences R&D teams with respect to day-to-day transactions
  • Experience reviewing and negotiating confidentiality agreements, material transfer agreements, sponsored research agreements, master services agreements, consulting agreements, and licenses
  • Experience working with data privacy and cybersecurity issues
  • Experience managing attorneys and/or non-attorney legal staff preferred
Responsibilities
  • Directs and implements 4DMT’s intellectual property strategy, and manages its patent, trade secret, and trademark portfolio; implements a strategy for IP lifecycle management.
  • Directs outside counsel in the preparation and prosecution of applications and responding to office actions; directs outside counsel in evaluating the patentability of invention submissions and registrability of trademarks globally; manages related outside counsel budgets.
  • Identifies strategic areas for patenting, trade secret protection, and trademarking; collaborates with R&D, Manufacturing, Clinical Science, and other functions to proactively identify and develop patentable intellectual property to prepare, file, and prosecute.
  • Manages patentability, freedom-to-operate, infringement, validity, and regulatory exclusivity analyses.
  • Identifies and tracks 4DMT trade secrets and provides counsel with respect to 4DMT’s trade secret protection practices.
  • Provides IP perspective and counseling at 4DMT meetings and presents on IP topics.
  • Counsels and trains internal clients on intellectual property practices and policies.
  • Conducts IP due diligence for business development activities and supports IP due diligence related to financing activities.
  • Drafts, reviews, and negotiates agreements to support R&D research activities, including NDAs, MTAs, MSAs, sponsored research agreements, consulting agreements, and licenses.
  • Collaborates with Legal colleagues, Business Development, and other key leaders and functions on key strategic agreements, including licenses, collaboration agreements, and other business development efforts.
  • Assists with other Legal Department matters, including litigation support, SEC reporting (IP-related sections), records management, compliance activities, and template projects.
Desired Qualifications
  • In-depth knowledge of the drug development process, regulatory and compliance requirements, strategic partnerships, and commercial strategy is strongly preferred.
  • Prior experience providing IP input on life sciences strategic transactions preferred.
  • Experience working with data privacy and cybersecurity issues.
4D Molecular Therapeutics

4D Molecular Therapeutics

View

4D Molecular Therapeutics develops gene therapies aimed at treating serious genetic diseases by delivering specific genetic material to patients' cells. The company utilizes a unique technology called Therapeutic Vector Evolution to create adeno-associated virus (AAV) vectors, which act as delivery vehicles for therapeutic genes targeting affected cells in the body. Unlike many competitors, 4DMT focuses on precision medicine for genetic disorders, including cystic fibrosis, and emphasizes rigorous research and clinical trials to ensure the safety and effectiveness of its therapies. The company's goal is to commercialize these gene therapies through direct sales or partnerships with larger pharmaceutical firms, while also securing funding to support its research and development efforts.

Company Size

201-500

Company Stage

IPO

Total Funding

$170.2M

Headquarters

Emeryville, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • 4DMT secured a $962 million deal with Astellas for their vector technology.
  • Positive interim data from 4D-710 trials show promise for cystic fibrosis treatment.
  • Series C financing raised $75 million, boosting research and development capabilities.

What critics are saying

  • Public stock offering may dilute existing shareholders' equity, causing dissatisfaction.
  • Analysts cutting estimates suggest potential financial instability or unmet expectations.
  • Reliance on partnerships like Astellas poses risk if outcomes don't meet expectations.

What makes 4D Molecular Therapeutics unique

  • 4DMT uses proprietary Therapeutic Vector Evolution for advanced AAV vector creation.
  • Their focus is on gene therapies for serious genetic diseases like cystic fibrosis.
  • 4DMT's R100 vector technology efficiently targets retinal cells for eye disease treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

0%

2 year growth

4%
GlobeNewswire
Mar 28th, 2024
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

EMERYVILLE, Calif., March 28, 2024 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced an update on its regulatory interactions and development path for 4D-710, an aerosolized genetic medicine for the treatment of CF lung disease.

Benzinga
Feb 6th, 2024
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast

Monday, 4D Molecular Therapeutics FDMT-5.21%+ Free Alerts released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients.

GlobeNewswire
Feb 5th, 2024
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

4D Molecular Therapeutics announces proposed public offering of common stock.

Simply Wall St
Nov 12th, 2023
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) just released its quarterly report and things are looking bullish.

Fabry Disease News
Nov 3rd, 2023
4DMT, FDA agree to lift clinical hold on Fabry gene therapy 4D-310

To address this, 4DMT launched a single safety study involving nonhuman primates to evaluate 4D-310 combined with an immunosuppressive regimen using rituximab and sirolimus (R/S) to lower the risk of aHUS and toxicity-related side effects.